Literature DB >> 16311929

Nicotine metabolism in healthy smokers and patients with cardiovascular diseases.

Ramez Chahine1, Antoine Abchee, Pierre Zalloua.   

Abstract

In this study, we measured the excretion rate of nicotine and its two major metabolites, cotinine and trans-3'-hydroxycotinine (THOC), in the urine of 25 healthy smokers and 15 smokers who underwent a coronary artery bypass surgery or coronary angioplasty. After 1 day of smoking cessation, urine samples were collected in the morning, before smoking two cigarettes, and then three times after smoking, approximately 4 h apart. The results show that (i) in healthy smokers, nicotine and its two major metabolites were present at high concentration in the first urine sample after smoking, (ii) in smokers with cardiovascular disease nicotine and cotinine were less excreted whereas THOC was more excreted, mainly in the second urine sample. We conclude that this shift in nicotine metabolism may contribute to smoking-induced cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16311929     DOI: 10.1007/s11010-005-8840-9

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  16 in total

1.  Evidence for urinary excretion of glucuronide conjugates of nicotine, cotinine, and trans-3'-hydroxycotinine in smokers.

Authors:  G D Byrd; K M Chang; J M Greene; J D deBethizy
Journal:  Drug Metab Dispos       Date:  1992 Mar-Apr       Impact factor: 3.922

2.  Reference interval and subject variation in excretion of urinary metabolites of nicotine from non-smoking healthy subjects in Denmark.

Authors:  A M Hansen ; A H Garde; J M Christensen; N Eller; L E Knudsen; R Heinrich-Ramm
Journal:  Clin Chim Acta       Date:  2001-02       Impact factor: 3.786

3.  A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes.

Authors:  E S Messina; R F Tyndale; E M Sellers
Journal:  J Pharmacol Exp Ther       Date:  1997-09       Impact factor: 4.030

Review 4.  Urinary cotinine as a tobacco-smoke exposure index: a minireview.

Authors:  V Haufroid; D Lison
Journal:  Int Arch Occup Environ Health       Date:  1998-05       Impact factor: 3.015

5.  Interindividual variability in the metabolism and cardiovascular effects of nicotine in man.

Authors:  N L Benowitz; P Jacob; R T Jones; J Rosenberg
Journal:  J Pharmacol Exp Ther       Date:  1982-05       Impact factor: 4.030

6.  Effects of nicotine on thromboxane/prostacyclin balance in myocardial ischemia.

Authors:  R Nemr; B Lasserre; R Chahine
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2003-03       Impact factor: 4.006

7.  Evidence that nicotine acetylcholine receptors are not the main targets of cotinine toxicity.

Authors:  O Riah; J C Dousset; P Courriere; J L Stigliani; G Baziard-Mouysset; Y Belahsen
Journal:  Toxicol Lett       Date:  1999-09-20       Impact factor: 4.372

8.  Nicotine metabolic profile in man: comparison of cigarette smoking and transdermal nicotine.

Authors:  N L Benowitz; P Jacob; I Fong; S Gupta
Journal:  J Pharmacol Exp Ther       Date:  1994-01       Impact factor: 4.030

9.  Determination of nicotine and its main metabolites in urine by high-performance liquid chromatography.

Authors:  P P Rop; F Grimaldi; C Oddoze; A Viala
Journal:  J Chromatogr       Date:  1993-02-26

Review 10.  Nicotine metabolism, human drug metabolism polymorphisms, and smoking behaviour.

Authors:  Anthony R Tricker
Journal:  Toxicology       Date:  2003-02-01       Impact factor: 4.221

View more
  1 in total

1.  Interactions between smoking, pulmonary surfactant protein B, and atherosclerosis in the general population: the Dallas Heart Study.

Authors:  Ann B Nguyen; Anand Rohatgi; Christine K Garcia; Colby R Ayers; Sandeep R Das; Susan G Lakoski; Jarett D Berry; Amit Khera; Darren K McGuire; James A de Lemos
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-08-04       Impact factor: 8.311

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.